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Hepatitis B virus (HBV) infection results in complications such as cirrhosis and hepatocellular
carcinoma. Suppressing viral replication in chronic HBV carriers is an effective approach to
controlling disease progression. Although antiviral compounds are available, we aimed to
identify host factors that have a significant effect on viral replication efficiency.
Methods and Findings
We studied a group of hepatitis B carriers by associating serum viral load with their
respective HBV genomes, and observed a significant association between high patient serum
viral load with a natural sequence variant within the HBV enhancer II (Enh II) regulatory region
at position 1752. Using a viral fragment as an affinity binding probe, we isolated a host DNA-
binding protein belonging to the class of heterogeneous nuclear ribonucleoproteins—hnRNP
K—that binds to and modulates the replicative efficiency of HBV. In cell transfection studies,
overexpression of hnRNP K augmented HBV replication, while gene silencing of endogenous
hnRNP K carried out by small interfering RNAs resulted in a significant reduction of HBV viral
load.
Conclusion
The evidence presented in this study describes a wider role for hnRNP K beyond
maintenance of host cellular functions and may represent a novel target for pharmacologic
intervention of HBV replication.
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Hepatitis B virus (HBV) infection is a serious public health
problem in many parts of Asia and Africa that results in
complications such as cirrhosis and cancer of the liver [1].
Globally, despite effective vaccination against HBV and
available antiviral treatments [2–7], there remain an esti-
mated 350 million hepatitis B carriers with a lifetime risk for
developing cirrhosis and hepatocellular carcinoma, as many
individuals infected during infancy remain infectious carriers
for decades. Although the association between HBV infection
and the development of liver cancer has stirred profound
interest in the development of therapeutics for both the
prevention of HBV infection and the clearance of virus from
chronic infection, HBV continues to be a pathogen of
signiﬁcant importance. Current antiviral therapies for HBV
carriers include treatment such as alpha-interferon or
lamivudine, but the long-term resolution of disease is
disappointing due to low seroconversion rates and the
development of drug-resistant viral mutants [7].
HBV belongs to a family of viruses known as Hepadnaviridae
and encodes only four genes in a highly compact viral
genome: the surface gene (S), the core gene (C), the X gene (X),
and the polymerase gene (P). Viral replication has been shown
to occur via an RNA intermediate in the cytoplasm, but,
unlike retroviruses, integration of HBV DNA into the host
genome is not required. Despite a wealth of information on
the virus itself and the possible role that host factors may play
in the viral infectious life cycle [8–11], the direct relationship
between chronically infected patients and host–pathogen
interactions is poorly understood.
Host cellular factor heterogeneous nuclear ribonucleopro-
teins (hnRNPs) are known to be pre-mRNA binding proteins
and shuttle intermediates between nucleus and cytoplasm.
hnRNP K in particular has been implicated in diverse
molecular and cellular functions, including nuclear–cytoplas-
mic shuttling [12], transcription, and translation [13]. Here,
we aimed to study the importance of hnRNP K in the
regulation of HBV viral replication.
Both over-expression and knockdown assays were designed
to enhance HBV viral load and to silence the endogenous
hnRNP K, respectively, within the cell to verify the effects of
hnRNP K on HBV viral replication.
Methods
Serological Assays
Serum samples were aliquoted and stored at  20 8C until
they were defrosted for testing. We examined serum HBV
DNA levels by the Hybrid Capture II HBV DNA Assay
(Digene, Gaithersburg, Maryland, United States).
PCR and Sequencing of the Enh II/Pre-Core Region
DNA extracted from serum was ampliﬁed with primers 59-
TTCACCTCTGCACGTCGC-39 and 59-GCTTGGAGGCTT-
GAACAG-39 (94 8C for 2 min, followed by 35 cycles of 94 8C
for 15 s, 50 8C for 30 s, and 72 8C for 1 min, and lastly followed
by 72 8C for 7 min) with Taq DNA polymerase (Roche, Basel,
Switzerland). Nested primers 59-GTCAACGACCGACCTT-
GAGG-39 and 59-ACCAATTTATGCCTACAGCCTC-39 were
used in a second round of PCR (94 8C for 2 min, followed by
35 cycles of 94 8C for 15 s, 55 8C for 30 s, and 72 8C for 1 min,
and lastly followed by 72 8C for 7 min). The size of this nested
PCR product was 116 base pairs (corresponding to nucleo-
tides 1682–1798) and was resolved in 1.5–2% agarose gels.
PCR products were cleaned up using the Qiaquick PCR
Puriﬁcation Kit (Qiagen, Valencia, California, United States)
and sequenced directly to conﬁrm the identity of the
products using the ABI prism dRodamine Terminator Cycle
Sequencing Ready Reaction Kit (ABI-Prism 310; Applied
Biosystems, Foster City, California, United States). Results of
the sequences were aligned and compared.
Construction of Plasmids
Plasmids pGL3-Control (a Luciferase plasmid with a simian
virus 40 enhancer and promoter) and pGL3-Promoter (an
enhancerless Luciferase plasmid with a simian virus 40
promoter upstream from the Luciferase gene) were obtained
from Promega (Madison, Wisconsin, United States). Plasmid
pGL3-Promo/A was constructed by amplifying the basic
functional unit of Enh II by PCR using primers LucF (59-
GCACGCGTCAACGACCGACCTTGAGG-39) and LucR (59-
GCAGATCTACCAATTTATGCCTACAGCCTC-39) comprising
HBV nucleotide positions 1686–1801. The 131-base-pair PCR
fragment was MluI/BglII-digested and ligated with MluI/BglII-
digested pGL3-Promoter. The other mutant constructs were
constructed using the Gene Editor Site-Directed in vitro
Mutagenesis System (Promega) to introduce the HBV Enh II
mutations at nucleotide position 1752. The ﬁrst mutation was
mutating nucleotide A to G (pGL3-Promo/G), the second was
with nucleotide A to T (pGL3-Promo/T), and the third was
with nucleotide A to C (pGL3-Promo/C). The sequences of the
three mutant oligonucleotides were 59-GGGGGAGGAGGT-
TAGGTTAAA-39,5 9-GGGGGAGGAGTTTAGGTTAAA-39,
and 59-GGGGGAGGAGCTTAGGTTAAA-39, respectively.
Constructs were sequenced for veriﬁcation. hnRNP K
‘‘variant 2’’ and ‘‘variant 3’’ clones were constructed by
cloning a 1.4-kb RT-PCR fragment coding for the hnRNP K
from total RNA extracted from HepG2 cells. The EcoRI- and
XhoI-digested PCR fragments were cloned into EcoRI- and
XhoI-digested pcDNA 3.1 separately. Cloning primers for
‘‘variant 2’’ were 59-TAAAAGGAATTCAATATGCAAACT-
GAACAG-39 and 59-CTAGTCCTCGAGTTA-
GAAAAACTTTCCAGA-39, and cloning primers for ‘‘variant
3’’ were 59-TAAAAGGAATTCAATATGCAAACTGAACAG-39
and 59-CTTGCACTCGAGTTAGAATCCTTCAACATC-39.
The HBV 1752A full-length replicative clone (genotype A)
was constructed by using a HBV genome-containing pBR325
plasmid (ATCC, Manassas, Virginia, United States) as a
template. Primers were designed to amplify two fragments:
1–1900 and 1600–3215. The region 1600–1900 contained the
core promoter and the overlapping transcription termina-
tion region [14] (Figure S1). In-frame ligation of the two
fragments using the internal EcoRI (1/3215) ensures contin-
uous viral open reading frames were cloned into the NruI site
in pcDNA 3.1, resulting in the replicative construct. Viral
transcription was under its own promoter control as the viral
insert was cloned at the NruI site, located upstream of the
plasmid’s CMV promoter [15]. The 1752DG, 1752DT, and
1752DC full-length replicative clones were constructed as
described for the 1752A. The ﬁrst fragment, 1600–3215, was
generated as a PCR product from the HBV-pBR325 plasmid
and cloned into pcDNA 3.1. The 1752G, 1752T, and 1752C
mutations were each generated separately in the ﬁrst
fragment by the Quick-Change site-directed mutagenesis kit
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was done for veriﬁcation of the constructs. The second
fragment, comprised of nucleotides 1–1900 of the HBV
insert, was generated by PCR from HBV-pBR325 and cloned
downstream of the ﬁrst fragment in pcDNA 3.1.
Cells
Four cell lines—HCCM, HepG2, PLC/PRF/5, and Sk-Hep-
1—derived from human hepatocellular carcinomas were used
in this study. HCCM and PLC/PRF/5 contained copies of the
integrated HBV genome, while HepG2 and Sk-Hep-1 were
obtained from patients with no history of HBV infection and
HBV genome integration [16–18]. Cells were cultured and
maintained in complete Dulbecco’s modiﬁed Eagle’s medium
(Invitrogen, Carlsbad, California, United States) and supple-
mented with 10% fetal bovine serum (Hyclone, South Logan,
Utah, United States) at 37 8C in humidiﬁed 5% carbon
dioxide.
Transient Transfection Assays
Cells were plated at an average seeding density of 1 3 10
6
cells per well in 35-mm tissue culture dishes and transfected
with Lipofectamine 2000 (Invitrogen) according to manufac-
turer’s instructions. Brieﬂy, 2 lg of plasmid DNA was used for
each transfection mix and added dropwise onto the cells.
After incubation for 48 h at 37 8C, the cells were subsequently
harvested, followed by DNA isolation (Qiagen). HBV viral
loads were measured by real-time PCR using the RealArt HBV
LC PCR Kit (Artus GmbH, Hamburg, Germany) according to
manufacturer’s instructions in the LightCycler Instrument
(Roche). Experiments were done in duplicate.
Luciferase Assays
For the luciferase assays, 3 lg of plasmid DNA together
with 1 lg of control/promoter luciferase plasmid-DNA was
used for each transfection mix, and, after incubation for 48 h
at 37 8C, cells were harvested with Cell Culture Lysis Reagent
(CCLR; Promega). Next, 20 ll of cell lysates was mixed with
100 ll of Luciferase Assay Reagent (Promega), and luciferase
activity was measured as relative light units determined with a
Turner 20/20 luminometer (Promega). Relative luciferase
activity was expressed as fold increase over vector without the
enhancer element. Experiments were performed in triplicate.
Preparation of Nuclear Protein Extracts and Gel-Shift
Assays
Cultures were trypsinized, rinsed twice with ice-cold 13
phosphate-buffered saline, and incubated on ice for 10 min
with 53original packed cell volume of Buffer A (10 mM N-2-
hydroxyethylpiperazine-N9-ethane sulfonic acid [HEPES] buf-
fer [pH 7.9], 1.5 mM magnesium chloride, 10 mM potassium
chloride, and 1 mM dithiothreitol [DTT]). After centrifuga-
tion at 1,000 rpm for 3 min at 4 8C, cells were re-suspended in
23original packed cell volume of Buffer A and homogenized
in a Dounce homogenizer with an S pestle with 10 strokes.
Nuclei fractions were sedimented by a 10-min centrifugation
at 2,500 rpm, re-suspended in 1.53 Buffer B (20 mM HEPES
[pH 7.9], 0.2 mM ethylene diamine tetra-acetic acid [EDTA],
1.5 mM magnesium chloride, 420 mM sodium chloride, 0.5
mM DTT, and 25% glycerol) and treated with another 10
strokes of Dounce homogenizer. Cell suspensions were then
transferred to microcentrifuge tubes and incubated for 30
min at 4 8C with gentle rotation. Nuclear debris was removed
by centrifugation at 13,000 rpm for 40 min at 4 8C. The
supernatant was dialyzed for 4 h against two changes of 200
ml Buffer C (20 mM HEPES [pH 7.9], 0.2 mM EDTA, 20 mM
magnesium chloride, 20 mM potassium chloride, 420 mM
sodium chloride, 25% glycerol, 0.5 mM DTT, and 0.5 mM
phenylmethylsulfonyl ﬂuoride) at 4 8C. After dialysis, nuclear
extracts were clariﬁed by centrifugation at 13,000 rpm for 20
min. Nuclear extracts were then aliquoted and stored at  80
8C. Protein concentration was quantitated with the Protein
Assay kit (Bio-Rad Laboratories, Hercules, California, United
States) using acetylated bovine serum albumin as standard.
Binding reaction procedures were performed at 37 8C for
20 min in 20-ll reaction mixtures (10 mM Tris-HCl [pH 7.5],
50 mM sodium chloride, 1 mM EDTA, and 1 mM DTT)
containing 10 lg of HepG2 nuclear extracts, 0.1–0.2 lgo f
non-speciﬁc competitor DNA poly (dI–dC) (Amersham
Pharmacia Biotech, Piscataway, New Jersey, United States),
and
32P-dATP end-labeled probe (1 3 10
4 to 1 3 10
5 cpm).
Free DNA and DNA–protein complexes were resolved on 6%
non-denaturing polyacrylamide gels. Gels were dried down
under vacuum at 80 8C for 1 h before exposure to X-ray ﬁlm
(Biomax; Eastman Kodak, Rochester, New York, United
States) at  80 8C. The sequences of the oligonucleotide




and Probe 4, AGTTGGGGGAGGAGGTTAGGTTAAAGGT.
Affinity Capture of Host-Interacting Proteins, Two-
Dimensional (2-D) Gel Electrophoresis, and Protein
Identification
Nuclear protein extracts were obtained from HepG2 cells.
HepG2 cells were harvested and rinsed twice with ice-cold
Buffer A (0.15 M sodium chloride and 10 mM HEPES [pH
7.4]), and incubated on ice for 15 min with 53original packed
cell volume of Buffer B (0.33 M sucrose, 10 mM HEPES, 1 mM
magnesium chloride, and 0.1% Triton X-100 [pH 7.4]). After
centrifugation at 3,000 rpm for 5 min at 4 8C, the pellet was
washed once with Buffer B and re-suspended gently on ice
with 200 ll of Buffer C (0.45 M sodium chloride and 10 mM
HEPES [pH 7.4]), with protease inhibitor cocktail [Sigma
P8340]). The cell mixture was incubated for 15 min with
gentle agitation followed by centrifugation at 13,000 rpm for
5 min. The supernatant was saved for DNA-binding proteins
assay. Annealing of double-stranded oligonucleotides probes
was done using 100 ll of deionized Milli Q water containing 1
nmol each of antisense probe and sense probe, which were
labeled with biotin at the 39 end, and 59 end, respectively.
Oligonucleotide mixture solutions were heated at 95 8C for 5
min and cooled slowly to room temperature. DNA-interact-
ing proteins were captured as described. The oligonucleotide
mixture was incubated with 5 mg Dynabeads M-280 strepta-
vidin (Dynal Biotech, Oslo, Norway) at room temperature for
15 min in binding and washing buffer (5 mM Tris-HCl, 0.5
mM EDTA, and 1.0 M sodium chloride [pH 7.5]). The
magnetic beads were then washed with binding and washing
buffer and equilibrated with TGED buffer (20 mM Tris-HCl,
10% glycerol, 1 mM DTT, 0.01% Triton X-100, and 50 mM
sodium chloride [pH 8.0]). 40 lg of extracted nuclear proteins
was mixed 2:1 (w/w) with non-speciﬁc competitor DNA poly
(dI–dC) (Amersham Biosciences, Little Chalfont, United
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proteins–poly (dI–dC) solution was added to the equilibrated
magnetic beads–oligonucleotide probe at room temperature
for 30 min. Unbound proteins were washed out with TGED
buffer. Bound proteins were eluted with TGED buffer with 1
M sodium chloride. The same capturing and elution
procedure was repeated another four times with new aliquots
of nuclear proteins–poly (dI–dC) mixture. Eluted fractions
were pooled and subjected to acetone precipitation. We
performed 2-D gel electrophoresis according to the Amer-
sham Biosciences protocol, with some modiﬁcations. Each
sample containing acetone-precipitated proteins was made
up to a volume of 350 ll with rehydration buffer (7 M urea, 2
M thiourea, 4% CHAPS, 0.5% IPG buffer [pH 3–10], and 1.0
mg of DTT). The mixture was mixed brieﬂy by vortexing, and
centrifuged at 13,000 rpm for 10 min. The supernatant was
loaded to 18 cm (pH 3–10) nonlinear Immobiline DryStrips
(Amersham Pharmacia Biotech), and rehydration was carried
out actively at constant voltage (50 V) overnight. Isoelectric
focusing was performed using IPGphor (Amersham Bioscien-
ces) at 20 8C in stepwise mode. Brieﬂy, strips were focused at
500 V for 1 h, 2,000 V for 1 h, 5,000 V for 1 h, and 8,000 V for
12 h, with a total of 90 kVh accumulated. After isoelectric
focusing, the IPG strips were incubated for 30 min in 15 ml of
SDS equilibration buffer (50 mM Tris-HCl, 6 M urea, 30%
glycerol, 2% SDS, 66 mM DTT, and a trace amount of
bromophenol blue [pH 8.8]), followed by second incubation
with the same buffer for 30 min with iodoacetamide (375 mg/
15 ml) instead of DTT. 2-D vertical SDS-PAGE (Protein II XL,
Bio-Rad Laboratories) was carried out using 10% gels at a
constant voltage of 150 V for 6–8 h at 15 8C. Gels were stained
with SilverQuest Silver Staining Kit (Invitrogen). Speciﬁc
protein spots were cored out and de-stained according to
manufacturer’s instructions, after which the gel plug was
dried and MS/MS analysis carried out by Proteomic Research
Services (Ann Arbor, Michigan, United States).
In-gel digestion. Samples were subjected to trypsin
digestion on a ProGest (Genomic Solutions, Ann Arbor,
Michigan, United States) workstation as follows: Gel plugs
were soaked in ammonium bicarbonate solution and reduced
with DTT. Alkylation was performed by using iodoacetamide.
Samples were incubated at 37 8C overnight in the presence of
trypsin. Formic acid was added to stop the reaction.
Liquid chromatography/tandem mass spectrometry (LC/
MS/MS) analyses: Peptides were cleaned up by using C18
ZipTips (Millipore, Billerica, Massachusetts, United States)
and eluted with matrix (a-cyano-4-hydroxycinnamic acid)
prepared in 60% acetonitrile and 0.2% TFA. 15 ll of eluent
was processed on a 75-lm C18 column at a ﬂow-rate of 20 nl/
min. Eluent from the C18 column was fed into nano-LC/MS/
MS on a Micromass Q-TOF2 mass spectrometer. MS/MS data
were searched using a local copy of MASCOT search engine
(Matrix Science, London, United Kingdom).
RNA Interference
Small interfering RNA (siRNA) duplexes against hnRNP K
were purchased from Dharmacon (SmartPool) (Lafayette,
Colorado, United States), Qiagen (sequence: GCAGUAUU-
CUGGAAAGUUU), and Proligo (sequence: CUUGGGACU-
CUGCAAUAGATT) (Boulder, Colorado, United States).
HepG2 cells were co-transfected in 24-well tissue culture
plates with 1 lg of plasmid DNA (1752A replicative full-
length clone) and the respective siRNA duplexes (2 lg) using 6
ll Lipofectamine 2000 (Invitrogen). After 48 h, the cells were
collected and were RNA and DNA extracted. As controls, cells
were also transfected with ﬂuorescence-labeled non-silencing
siRNA to monitor the transfection efﬁciencies. Transfections
were performed in duplicate.
Quantitation of hnRNP K Expression
Total RNA was isolated with RNeasy kit (Qiagen) according
to the manufacturer’s instructions. The concentration and
purity of extracted RNA were determined by measuring the
A260 and A280, and adjusted to 250 ng/ll, which was then used
as a template for real-time RT-PCR. 2 ll of RNA was used in a
one-step real-time RT-PCR reaction with the LightCycler
RNA Master SYBR Green kit (Roche) using primers 59-
AGACCGTTACGACGGCATGGT-39 and 59-GATC-
GAAGCTCCCGACTCATG-39, and performed according to
manufacturer’s instructions. Absolute quantitation of RNA
was obtained by using standard curves created with in vitro–
transcribed RNA by the T7 RiboMax Express in vitro
transcription system (Promega). The concentration of puri-
ﬁed transcribed RNA was measured by RiboGreen RNA
quantitation reagent (Invitrogen). Serial dilutions of in vitro–
transcribed RNA were prepared in duplicate.
Statistical Analysis
A multi-alignment sequence analysis of the HBV genomes
with ranked HBV viral load was ﬁrst performed, and we
compared the frequencies of the mutations at nucleotide
position 1752 using Fisher’s exact probability test.
Results
Correlation between High and Low Viral Loads in Patients
at a Precise Location in the HBV Genome
To study the inﬂuence of HBV variants on the resultant
dynamics of viremia in HBV carriers, we analyzed serum
samples from 60 carriers for viral load using a commercially
available test kit (Digene). The serum viral load among HBV
carriers (Figure 1) was found to vary by more than three
orders of magnitude (0.1–376 pg/ml). About 60% (36/60) of
the carriers had single-digit pg/ml (0.1–5 pg/ml) concentration
of viral DNA, while 40% (24/60) had greater than 10 pg/ml
(11–376 pg/ml) concentration (Figure 1). To determine if viral
variants had any link with viral load in the carriers, we
ampliﬁed HBV DNA by PCR from serum, sequenced, and
aligned the ampliﬁed fragments. Interestingly, within the
entire viral genome, we observed a unique nucleotide
position that showed signiﬁcant correlation (p ¼ 0.0001) with
viral load as deﬁned by the two broadly partitioned groups of
serum viral load described above (using 10 pg/ml as an
arbitrary cut-off). As there was no particular physiological
phenotype linked to a threshold HBV viral load, we also
applied cut-off values of 20 pg/ml and 50 pg/ml; in both
instances, the results were similar to the 10-pg/ml value (data
not shown). Although the HBV genotypes were predomi-
nantly genotype C, we observed a distinct tendency for
carriers with high levels of serum HBV DNA to possess an A
nucleotide at position 1752 of the virus sequence, while those
with low levels of serum HBV DNA tend to have a G
nucleotide at this position. This natural variation at nucleo-
tide position 1752 was found to be located at the HBV
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regulator of HBV replication [8,9,11,19,20].
Natural Mutants of HBV with Different Viral Replication
Efficiencies
As this variation resided in the viral enhancer element
(Figure 2A), we proceeded to study the effects of this base
substitution on transcriptional efﬁciency by cloning a 131-
base-pair Enh II fragment bearing 1752A upstream of a SV40
promoter–luciferase reporter gene vector. Site-directed
mutagenesis was then carried out to generate three other
constructs bearing 1752G, 1752T, and 1752C so that four
constructs differing from each other at only this single base
nucleotide could be tested (Figure 2B). Transient trans-
fections were carried out on the hepatic cell line HepG2 and
subsequently assayed for luciferase activity. The results
showed that the construct with 1752A strongly enhanced
the SV40 promoter when linked to it in cis, resulting in higher
levels of luciferase expression as compared to all other base
substitutions (Figure 2C). As a positive control, the vector
containing both the SV40 promoter and enhancer sequences
resulting in optimal luciferase expression was used (‘‘þ’’ in
Column 1 in Figure 2C). In addition, the cloning vector itself
containing only the SV40 promoter–luciferase gene but
without the enhancer element (‘‘ ’’ in Column 2 in Figure
2C) served as the negative control. To determine if these
results were speciﬁc to only the host HepG2 cell line, we
repeated the transfections in three other hepatic cell lines:
Figure 1. Distinct Segregation between High and Low Viremic HBV Individuals Is Correlated to Changes at Nucleotide Position 1752
Comparison of DNA sequences from nucleotide 1720–1769 with the HBV DNA concentration levels of the participants are illustrated. Sera was collected
from 60 participants; DNA was isolated from sera and amplified with two rounds of PCR. Results of the sequences were aligned and compared.
DOI: 10.1371/journal.pmed.0020163.g001
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hnRNP K As a Target to Suppress HBVSKHep1, PLC/PRF/5, and HCCM. The results were consistent
with the initial results observed with HepG2 (Figure 2D, 2E,
and 2F), further substantiating that the single base change at
nucleotide position 1752 has a signiﬁcant effect on the
transcriptional efﬁciency of Enh II. These in vitro assays
provide strong support for the effect of 1752A on higher
HBV viral load, but it is worthwhile to note that this
correlation is not absolute. As can be seen in Figure 1, the
nucleotide change in 1752A cannot alone account for the
wide variation in HBV viral load, suggesting that there may be
additional contributing factors. Subsequent experiments
were carried out using the HBV negative HepG2 cell line,
as it has better growth characteristics than SKHep1, while
PLC/PRF/5 and HCCM have integrated HBV genomes.
Identification of Host Cellular Factor as hnRNP K
In order to further establish and conﬁrm the biological
signiﬁcance of this point mutation observed in the Enh II
region, we wanted to demonstrate the presence of any direct
physical HBV DNA–host interaction at the nucleotide
position 1752 site. To this end, 28-mer oligonucleotide
probes were designed to contain either the 1752A or 1752G
nucleotide, with control probes taken from the immediate
adjacent upstream sequence. Electrophoretic mobility shift
assays were performed using HepG2 nuclear extracts with the
respective probes, and the results showed a distinct DNA-
binding protein was detected using the 1752A probe (Probe 2,
lanes 5–8 in Figure 3A) along with a weaker band of similar
size using the 1752G probe (Probe 4, lanes 13–16 in Figure
3A). Densitometric analysis of the bands indicated that the
protein detected by Probe 2 was about 300% higher than that
detected by Probe 4, suggesting that the 1752A probe has a
higher binding afﬁnity for the DNA-binding protein. These
data lend support to the possibility that host DNA-binding
proteins interact directly with the HBV viral sequence.
To further characterize this DNA-binding protein, nuclear
extract of HepG2 was passed through an afﬁnity column
tagged with the oligonucleotide probe (bearing 1752A).
Bound material was eluted and subjected to 2-D gel analysis.
Silver staining of the gels demonstrated positive enrichment
of a speciﬁc DNA-binding protein compared with the non-
speciﬁc binding control oligonucleotide probe (Figure 3B).
The speciﬁc protein spots of approximately 56 kDa molecular
weight were cored out and subjected to LC/MS/MS analysis
(Figure 4A). Peptide sequencing results showed that 21
fragments of the unknown DNA-binding protein turned out
to match perfectly with that of a known protein, hnRNP K
(Figure 4B). The peptide sequence match and molecular
weight of the predicted protein strongly suggest that the LC/
MS/MS analysis has correctly identiﬁed the protein bound by
the oligonucleotide-afﬁnity column. The hnRNP K protein,
which belongs to the family of hnRNPs, is about 56 kDa in size
and has been shown to be involved in various cellular
functions as described above.
hnRNP K Is an Essential Modulator of Viral Replication
To demonstrate the functional connection of hnRNP K to
the regulation of HBV viral load, a 1.4-kb RT-PCR fragment
coding for the full-length hnRNP K gene from total RNA
extracted from HepG2 cells was cloned into the mammalian
expression vector pcDNA 3.1 (Invitrogen). There are two
known variants of hnRNP K, termed ‘‘variant 2’’ and ‘‘variant
3,’’ which differ only at the last six amino acid residues of the
C-terminal region. As there are no reported studies on the
functional difference between the two variants, we decided to
work with both variants. The two hnRNP K expression
constructs were co-transfected separately into HepG2,
together with a full-length 1752A replicative clone of HBV
driven by the HBV core promoter rather than the CMV
promoter [14,15] (see Figure S1) to determine the effects of
hnRNP K on the replicative efﬁciency of the HBV construct.
As predicted, the HBV viral concentration increased in a
dose-dependent manner with hnRNP K concentration, with
no signiﬁcant functional difference between variants 2 and 3
(Figure 5). As a control, the empty expression vector pcDNA
3.1 did not have any effect on the HBV viral concentration.
To further verify the impact of the single-base substitution at
nucleotide position 1752, site-directed mutagenesis was
carried out to generate three other full-length HBV repli-
cative constructs bearing 1752DG, 1752DT, and 1752DC. Co-
transfections with either hnRNP K variant 2 or variant 3 were
performed as described above. All three constructs had 68–
80% reduced HBV DNA when compared to the 1752A
construct, indicating a lowered level of HBV viral load (Figure
5), although a high dosage of hnRNP K was able to augment
the replication efﬁciency of the three constructs. Taken
together, this set of co-transfection experiments provide
d e ﬁ n i t i v ee v i d e n c et h a tw eh a v ep r e c i s e l ym a p p e da n
important virus element and associated host component
required for regulating HBV replication.
As a further critical proof of the regulatory role of hnRNP
K in HBV viral load, the converse experiments to knock down
hnRNP K should show a suppressive effect on viral load. To
do this, siRNAs against hnRNP K were designed and obtained
from three separate manufacturers. HepG2 cells were co-
transfected with the replicative HBV full-length clone
(1752A) together with the panel of hnRNP K siRNAs, and
mRNA and DNA were analyzed 48 h after siRNA transfection.
Non-silencing siRNA not matching to any genes and lamin A/
C siRNAs were used as controls. The resultant hnRNP K
mRNA levels as measured by quantitative real-time RT-PCR
showed a 30% reduction relative to the non-transfected cells,
non-silencing siRNA, and lamin A/C siRNA controls (Figure
6A). HBV viral loads were correspondingly decreased by 50%
using both siRNAs from source B and C, while the siRNAs
from source A achieved a 15% reduction (Figure 6B). The
difference in effectiveness of siRNA from the three sources
may be due to the different target regions that are selected to
knock down hnRNP K, but the general suppressive trend was
clear (see Methods). The lamin A/C mRNA levels measured by
real-time RT-PCR in HepG2 cells transfected with lamin A/C
siRNA showed a 45% reduction relative to the non-trans-
fected cells, while non-silencing siRNA and hnRNP K siRNAs
had no effect on the lamin A/C mRNA levels (Figure 6C).
Taken together, these results conﬁrm that hnRNP K plays a
critical role in the process of HBV replication. The
observation that changes in intracellular hnRNP K levels
(both up and down) directly alter HBV replication efﬁciency
points to a regulatory role for hnRNP K.
Discussion
In this study, we were able to show that a host protein—
hnRNP K—can be isolated by direct binding to a viral
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patient, and that hnRNP K binds to and modulates the
replicative efﬁciency of HBV at a precise location at the Enh
II regulatory region. Overexpression studies and RNA
interference studies show a direct demonstration of the
dependence of HBV on a host factor to modulate its
replication efﬁciency, and hold promise as a new class of
targets for the intervention of chronic hepatitis B infection.
The interesting observation that chronic HBV carriers have
different serum viral loads spanning three logs (0.1–376 pg/ml
in this study) between patients prompted us to investigate the
possible correlation with viral genotype. While no such
particular relationship emerged, we detected a solitary yet
distinct natural mutation at nucleotide position 1752 that
had an ‘‘A’’ that segregated with viral loads greater than 10
pg/ml, while those with ‘‘G’’ segregated with the samples of
lower than 10 pg/ml. Of the 60 HBV genomes sequenced, only
one sample showed a ‘‘T’’ at position 1752, while ‘‘A’’ and ‘‘G’’
variants were present in almost equal proportions. No natural
‘‘C’’ variant was seen, but this could be due to our limited
sample size or an effect related to geographical distribution
patterns.
To understand whether the natural variants at 1752 had
any functional impact, we developed reporter constructs and
tested all four possible 1752 variants for the ability to drive
reporter gene transcription. It was evident that 1752A had
higher activity than the three other non-A constructs. To
investigate the underlying basis for this enhanced transcrip-
tional activity, we proposed to search for evidence of possible
physical interaction with DNA-binding proteins. Using an
initial electrophoretic mobility shift assay followed by an
afﬁnity pull-down assay run on 2-D gel analysis, a 1752A
oligonucleotide-afﬁnity fragment was able to enrich a host
binding factor sufﬁcient for protein sequencing. The binding
factor turned out to be hnRNP K, a known protein that has
been shown to be involved in a number of cellular functions
Figure 2. Effect of Nucleotide 1752 Base Substitution on Enh II Activity
(A) The Enh II is located just upstream of the core promoter. The minimum sequence for enhancer activity has been previously defined at nucleotide
1687–1805 as shown.
(B) Site-directed mutagenesis on nucleotide 1752 in the Enh II (1752A, 1752G, 1752T, and 1752C) and amplified fragments were inserted upstream of
the SV40 promoter in an enhancerless luciferase reporter vector.
(C–F) Four cell lines—HepG2, PLC/PRF/5, SKHep1, and HCCM, all derived from human hepatocellular carcinomas—were transfected with the respective
Enh II clones (1752A, 1752G, 1752T, and 1752C). For each cell type, the first column (‘‘þ’’) represents the luciferase activity of the internal positive control
(promoter and enhancer). The second column (‘‘ ’’) represents the activity of the internal negative control (promoter only). The other columns of each
cell line represent the vectors with the promoter and the Enh II (nucleotide 1752A, 1752G, 1752T, or 1752C). Results of the luciferase assay were
normalized to the level of the internal positive control (arbitrarily set at 100%).
DOI: 10.1371/journal.pmed.0020163.g002
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homology domains [21] and RGG boxes that allow it to
interact with both DNA and RNA [22–25]. Reports have
indicated that interactions between hnRNP K and single-
stranded DNA are mediated by three K homology domains
[21], and that hnRNP K exhibits speciﬁc binding and
transactivation within the c-myc promoter [26–30]. hnRNP K
was also shown to interact physically with the proto-
oncogenes c-src and vav [22,24,31,32], thus allowing it to form
multienzyme complexes and facilitate kinase cross-talk. This
result suggests that hnRNP K is a versatile molecule that can
act as a regulator of signal transduction and gene expression.
An important next step was to show that hnRNP K acts on a
full-length HBV genome and not just the 131-bp enhancer
fragment that was tested earlier in the luciferase reporter
assay. To this end, we constructed four full-length replicative
HBV clones, which were identical except for a single base
change at position 1752. Each replicative clone variant was
co-transfected with two different hnRNP K expression
constructs that represent the two known hnRNP K variants,
differing only at the C-terminal end of six amino acids. The
results once again conﬁrmed that the 1752A was more
efﬁcient than the other three variants, while there was no
signiﬁcant difference between either variant of hnRNP K in
enhancing viral load. With escalating doses of hnRNP K, the
viral load of the 1752G, 1752T, and 1752C variants increased
in a dose-dependent manner. This suggests that the increased
cellular concentrations of hnRNP K compensated to some
degree for the reduced afﬁnity bought about by the
nucleotide substitutions.
In order to further demonstrate the role of hnRNP K in
HBV replication, we wanted to test not only over-expression
Figure 3. Evidence for the Involvement of a Host Cellular Protein in Enh II Activity and HBV Replication
(A) Electrophoretic mobility shift assays were performed using HepG2 nuclear extracts with four different probes. Probe 1, lanes 1–4; probe 2 (1752A),
lanes 5–8; probe 3, lanes 9–12; probe 4 (1752G), lanes 13–16. Each set of probes contains increasing concentrations (0.0 lg, 0.05 lg, 0.10 lg, and 0.15
lg) of non-specific competitor DNA [poly-(dI)-poly-(dC)], respectively.
(B) 40 lg of nuclear protein extracts obtained from HepG2 cells was allowed to bind onto 5 mg Dynabeads M-280 streptavidin-biotin-oligonucleotides
in the presence of 2:1 (w/w) ratio of non-specific competitor DNA poly (dI–dC). 1-D isoelectric focusing was followed by 2-D vertical separation on SDS-
PAGE (10%). The estimated molecular weight of the specific protein spots detected by silver staining (arrow) is indicated.
DOI: 10.1371/journal.pmed.0020163.g003
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could have an effect. siRNAs designed to knock down
endogenous hnRNP K were able to suppress both hnRNP K
mRNA, and, along with it, the HBV viral load was greatly
reduced. More importantly, the inclusion of control siRNA to
lamin A/C suppressed lamin A/C mRNA but had no effect on
HBV viral load, thus strengthening the link between hnRNP K
and HBV.
Figure 4. Identification of Host Cellular Protein as hnRNP K
(A) Specific protein spots were cored out and de-stained, following which the gel plug was digested with trypsin. Sequence query of peptide fragments
was carried out by Proteomic Research Services, using LC/MS/MS analysis. Results of the 21 sequenced peptides are illustrated.
(B) Results of peptide sequencing of the 56-kDa protein by LC/MS/MS showed high homology scores to hnRNP K in sequence alignments.
DOI: 10.1371/journal.pmed.0020163.g004
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hnRNP K As a Target to Suppress HBVThe mechanistic aspect of hnRNP K on HBV replication
needs to be further explored, and efforts are currently under
way. There are possibilities such as hnRNP K polymorphisms
[33] (see Figure S2), phosphorylation states [21,22], transcrip-
tional regulation, and perhaps other cellular protein factors
that may act in concert to support the replication activity of
HBV in the host. That hnRNP K binding is mapped precisely
to a single-base polymorphism in the HBV genome’s
regulatory region suggests that a dynamic interaction exists
between speciﬁc natural mutants of the HBV Enh II region
and the patient’s genotype composition that together
function to determine the overall outcome of viral repli-
cation efﬁciency. Indeed, a deeper understanding of how this
works will provide insights into deﬁning virulence and ﬁtness
of a virus.
Our study shows that the overall viral replication efﬁciency
is determined by a combination of both viral sequence and
interaction with speciﬁc host proteins. While development of
antivirals is an established path, targeting the host remains
surprisingly unexplored. Interestingly, a recent study on anti-
EGFR antibody treatment of breast cancer cells showed a
decrease in the cell-replication rate with a corresponding
reduction in hnRNP K expression levels [34]. This suggests
that hnRNP K levels can be modulated by anti-EGFR
treatment and holds possibilities for new indications for
existing and approved pharmaceuticals as an approach to
alter HBV viral load in chronic carriers. Overcoming
entrenched, chronic viral infections is not a straightforward
solution and will eventually involve a combination therapy of
targeting the virus directly, blocking host support proteins,
and simultaneously employing immuno-modulating agents to
bring about long-term viral clearance.
Acknowledgments
We thank D. Simarmata, D. Kwek, L. V. Agathe, P. Tay (Genome
Institute of Singapore), and H. Pan (Nanyang Technological
University) for their excellent technical support, and E. Liu for
helpful comments. We also thank the following contributors for
patients’ serum used in this study: National University Hospital,
Singapore General Hospital, and Tan Tock Seng Hospital. This work
Figure 5. hnRNP K Is Involved in Modulating Viral Replication
HepG2 cells were co-transfected with full-length replicative HBV clones
(indicated by ‘‘þ’’) 1752A, 1752DG, 1752DT, and 1752DC (see Methods
and Figure S1) with increasing dosages (50, 250, and 1,250 ng/ll) of
hnRNP K variant 2 (v2) or variant 3 (v3) as indicated. pcDNA 3.1 serves as
a control. Transfections were performed in duplicate; standard deviations
are shown.
DOI: 10.1371/journal.pmed.0020163.g005
Figure 6. hnRNP K siRNAs Down-Regulate HBV Viral Replication
(A) HepG2 cells were co-transfected with 1752A full-length replicative HBV clone either with or without hnRNP K siRNA (2 lg). Non-silencing (Non-T)
and lamin A/C (Lamin) siRNAs were used as controls. hnRNP K expression was measured by quantitative real-time RT-PCR.
(B) HBV viral load was quantitated by real-time PCR in cells transfected as described in (A).
(C) Lamin A/C expression was measured from real-time RT-PCR. Ratios were normalized to 100% for the non-transfected cells. The results represent two
independent samples; standard deviations are shown.
Black columns represent either non-transfected cells or cells transfected with non-silencing siRNA. White columns represent cells co-transfected with
HBV and lamin A/C siRNA. Grey columns represent cells co-transfected with HBV and hnRNP K siRNAs (A, Dharmacon; B, Qiagen; C, Proligo).
DOI: 10.1371/journal.pmed.0020163.g006
PLoS Medicine | www.plosmedicine.org July 2005 | Volume 2 | Issue 7 | e163 0682
hnRNP K As a Target to Suppress HBVwas supported by funding from the Agency of Science and
Technology Research (A*STAR), Singapore. LFPN is supported by a
Postdoctoral Fellowship from the Singapore Millennium Foundation.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Supporting Information
Figure S1. Construction of the Full-Length HBV Replicative Clone
Found at DOI: 10.1371/journal.pmed.0020163.sg001 (53 KB PDF)
Figure S2. SNPs in the hnRNP K Gene from 18 Volunteers Compared
with SNPs Extracted from Ensembl and Celera Databases
Found at DOI: 10.1371/journal.pmed.0020163.sg002 (59 KB PDF)
References
1. Blumberg BS (1997) Hepatitis B virus, the vaccine, and the control of
primary cancer of the liver. Proc Natl Acad Sci U S A 94: 7121–7125.
2. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, et al. (1980)
Hepatitis B vaccine: Demonstration of efﬁcacy in a controlled clinical trial
in a high-risk population in the United States. N Engl J Med 303: 833–841.
3. Francis DP, Hadler SC, Thompson SE, Maynard SE, Ostrow DG, et al. (1982)
The prevention of hepatitis B with vaccine: Report of the Centers for
Disease Control multi-center efﬁcacy trial among homosexual men. Ann
Intern Med 97: 362–366.
4. Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, et al.
(1981) Randomised placebo-controlled trial of hepatitis B surface antigen
vaccine in French haemodialysis units: I, medical staff. Lancet 1: 455–459.
5. Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, et al.
(1981) Randomised placebo-controlled trial of hepatitis B surface antigen
vaccine in French haemodialysis units: II, haemodialysis patients. Lancet 1:
797–800.
6. Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, et al. (1985) Perinatal
hepatitis B virus transmission in the United States: Prevention by passive-
active immunization. JAMA 253: 1740–1745.
7. Hoofnagle JH, DiBisceglie AM (1997) The treatment of chronic viral
hepatitis. N Engl J Med 336: 347–356.
8. Nassal M (1998) Hepatitis B virus replication: Novel roles for virus-host
interactions. Intervirology 42: 100–116.
9. Seeger C, Mason W (2000) Hepatitis B virus biology. Microbiol Mol Biol Rev
64: 51–68.
10. Ganem D (2001) The X ﬁles—One step closer to closure. Science 294: 2299–
2300.
11. Tang H, Banks KE, Anderson AL, McLachlan A (2001) Hepatitis B virus
transcription and replication. Drug News Perspect 14: 325–334.
12. Michael WM, Eder PS, Dreyfuss G (1997) The K nuclear shuttling domain: A
novel signal for nuclear import and nuclear export in the hnRNP K
protein. EMBO J 16: 3587–3598.
13. Bomsztyk K, Van Seuningen I, Suzuki H, Denisenko O, Ostrowski J (1997)
Diverse molecular interactions of the hnRNP K protein. FEBS Lett 403:
113–115.
14. Weiss L, Kekule AS, Jakubowski U, Burgelt E, Hofschneider PH (1996) The
HBV-producing cell line HepG2-4A5: A new in vitro system for studying
the regulation of HBV replication and for screening anti-hepatitis B virus
drugs. Virology 216: 214–218.
15. Chen WN, Oon CJ, Toh I (2000) Altered antigenicities of a hepatitis B virus
surface antigen carrying mutations outside the common ‘‘a’’ determinant.
Am J Gastroenterol 95: 1098.
16. Aden DP, Fogel A, Plotkin S, Knowles SS (1979) Controlled synthesis of
HBsAg in a differentiated human liver carcinoma-derived cell line. Nature
282: 615–616.
17. Fogh J, Wright WC, Loveless JD (1977) Absence of Hela cell line
contamination in 169 cell lines derived from human tumors. J Natl Cancer
Inst 58: 209–214.
18. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J (1982) Growth of
human hepatoma cell lines with differentiated functions in chronically
deﬁned medium. Cancer Res 42: 3858–3863.
19. Su H, Yee JK (1992) Regulation of hepatitis B virus gene expression by its
two enhancers. Proc Natl Acad Sci U S A 89: 2708–2712.
20. Yee JK (1989) A liver-speciﬁc enhancer in the core promoter region of
human hepatitis B virus. Science 246: 658–661.
21. Braddock DT, Baber JL, Levens D, Clore GM (2002) Molecular basis of
sequence-speciﬁc single-stranded DNA recognition by KH domains:
Solution structure of a complex between hnRNP K KH3 and single-
stranded DNA. EMBO J 21: 3476–3485.
22. Van Seuningen I, Ostrowski J, Bomsztyk K (1995) Description of an IL-1
responsive kinase that phosphorylates the K protein. Enhancement of
phosphorylation by selective DNA and RNA motifs. Biochemistry 34: 5644–
5650.
23. Van Seuningen I, Ostrowski J, Bustelo XR, Sleath P, Bomsztyk K (1995) The
K protein domain that recruits the interleukin1-responsive K protein
kinase lies adjacent to a cluster of c-Src and Vav SH3-binding sites. J Biol
Chem 270: 26976–26986.
24. Denisenko O, O’Neill B, Ostrowski J, Van Seuningen I, Bomsztyk K (1996)
Zik1, a transcriptional repressor that interacts with the heterogeneous
nuclear ribonucleoprotein particle K protein. J Biol Chem 271: 27701–
27706.
25. Tomonaga T, Levens D (1995) Heterogeneous nuclear ribonucleoprotein K
is a DNA-binding transactivator. J Biol Chem 270: 4875–4881.
26. Takimoto M, Tomonaga T, Matinus M, Avigan M, Krutzsch H, et al. (1993)
Speciﬁc binding of heterogeneous ribonucleoprotein particle protein K to
the human c-myc promoter, in vitro. J Biol Chem 268: 18249–18258.
27. Micheolotti EF, Tomonaga T, Krutzsch H, Levens D (1995) Cellular nucleic
acid binding protein regulates the CT element of the human c-myc
protooncogene. J Biol Chem 270: 9494–9499.
28. Micheolotti GA, Micheolotti EF, Pullner A, Duncan RC, Eick D, et al. (1996)
Multiple single-stranded cis elements are associated with activated
chromatin of the human c-myc gene in vivo. Mol Cell Biol 16: 2656–2669.
29. Tomonaga T, Levens D (1996) Activating transcription from single-
stranded DNA. Proc Natl Acad Sci U S A 93: 5830–5835.
30. Tomonaga T, Micheolotti GA, Libutti D, Uy A, Sauer B, et al. (1998)
Unrestraining genetic processes with a protein-DNA hinge. Mol Cell 1:
759–764.
31. Ostareck-Lederer A, Ostareck DH, Cans C, Neubauer G, Bomsztyk K, et al.
(2002) c-Src-mediated phosphorylation of hnRNP K drives translational
activation of speciﬁcally silenced mRNAs. Mol Cell Biol 22: 4535–4543.
32. Taylor SJ, Shalloway D (1994) An RNA-binding protein associated with Src
through its SH2 and SH3 domains in mitosis. Nature 368: 867–871.
33. Dejgaard K, Leffers H, Rasmussen HH, Madsen P, Kruse TA, et al. (1994)
Identiﬁcation, molecular cloning, expression and chromosome mapping of
a family of transformation upregulated hnRNP-K proteins derived by
alternative splicing. J Mol Biol 236: 33–48.
34. Mandal M, Vadlamudi R, Nguyen D, Wang RA, Costa L, et al. (2001) Growth
factors regulate heterogeneous nuclear ribonucleoprotein K expression
and function. J Biol Chem 276: 9699–9704.
Patient Summary
Background Hepatitis B is a virus that can cause long-term health
problems, including cirrhosis of the liver and liver cancer in people who
are not able to clear the virus from their body. Although some drugs can
suppress the multiplication of the virus, these drugs do not cure the
patient of hepatitis B. Another way of tackling the virus might become
clear if it were known exactly how the virus interacts with the patient’s
cells.
What Did the Researchers Do? They noticed that among patients who
carried the hepatitis B virus (HBV), some had higher amounts of the virus
in their blood compared to others. The patients with higher levels
tended to have a virus that had one particular DNA type, and this
particular virus type could bind more closely to a protein found in
humans: hnRNP K. In the laboratory, when the investigators increased
the amount of this protein in cells infected with HBV, the virus multiplied
more; when they decreased it, the virus multiplied less.
What Does This Mean? This work suggests that one way to control the
multiplication of HBV in infected people is indirectly, by altering levels of
the protein hnRNP K. The next step will be to identify ways to do this
safely and reliably.
Where Can I Get More Information? Medline Plus has a section on
hepatitis B:
http://www.nlm.nih.gov/medlineplus/ency/article/000279.htm
The World Health Organization has a set of information on hepatitis,
including hepatitis B:
http://www.who.int/topics/hepatitis/en/
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